Phil Marder

Phil received a master's degree in microbiology from The Ohio State University in 1973 and joined Eli Lilly & Company as an associate biologist that same year. Phil has climbed through the ranks at Lilly to become a Research Advisor mainly through his successful leveraging of flow cytometry for drug discovery and development. Phil has co-authored over 45 peer-reviewed scientific articles and made multiple oral presentations. He has been a member of ISAC for over 25 years and has been an open advocate for promoting industrial scientists' research for mainstream recognition. Phil also serves on the GLIIFCA steering committee and is co-chair of the Indy Flow Users Group. Most recently, Phil has championed the use of flow cytometry for biomarker assays during clinical trials of new drug candidates.

Campaign Statement

I have been using flow cytometry and cell sorting for drug discovery and development for over 25 years and remain fully convinced of its unique place and value for cell biology research. Because ISAC is the center of excellence for this technology, I want our Society to prosper and grow in the future. Toward this goal, if elected, I will continue to endorse and promote membership into ISAC to all scientists, including those from both the academic and applied research sectors. Additionally, I would encourage these new members to take an active role in ISAC functions in order to infuse fresh ideas and enthusiasm into our organization's structure.